327 related articles for article (PubMed ID: 23833274)
61. Role of cytokines and chemokines in non-alcoholic fatty liver disease.
Braunersreuther V; Viviani GL; Mach F; Montecucco F
World J Gastroenterol; 2012 Feb; 18(8):727-35. PubMed ID: 22371632
[TBL] [Abstract][Full Text] [Related]
62. Inflammatory mediators of hepatic steatosis.
Hijona E; Hijona L; Arenas JI; Bujanda L
Mediators Inflamm; 2010; 2010():837419. PubMed ID: 20300479
[TBL] [Abstract][Full Text] [Related]
63. Role of transcription factor modifications in the pathogenesis of insulin resistance.
Kim MY; Bae JS; Kim TH; Park JM; Ahn YH
Exp Diabetes Res; 2012; 2012():716425. PubMed ID: 22110478
[TBL] [Abstract][Full Text] [Related]
64. A narrative review: CXC chemokines influence immune surveillance in obesity and obesity-related diseases: Type 2 diabetes and nonalcoholic fatty liver disease.
Ullah A; Ud Din A; Ding W; Shi Z; Pervaz S; Shen B
Rev Endocr Metab Disord; 2023 Aug; 24(4):611-631. PubMed ID: 37000372
[TBL] [Abstract][Full Text] [Related]
65. Does Diacylglycerol Accumulation in Fatty Liver Disease Cause Hepatic Insulin Resistance?
Finck BN; Hall AM
Biomed Res Int; 2015; 2015():104132. PubMed ID: 26273583
[TBL] [Abstract][Full Text] [Related]
66. Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance.
Jornayvaz FR; Shulman GI
Cell Metab; 2012 May; 15(5):574-84. PubMed ID: 22560210
[TBL] [Abstract][Full Text] [Related]
67. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome.
Jornayvaz FR; Samuel VT; Shulman GI
Annu Rev Nutr; 2010 Aug; 30():273-90. PubMed ID: 20645852
[TBL] [Abstract][Full Text] [Related]
68. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis.
Maher JJ; Leon P; Ryan JC
Hepatology; 2008 Aug; 48(2):670-8. PubMed ID: 18666225
[TBL] [Abstract][Full Text] [Related]
69. New insights into the pathophysiology of nonalcoholic fatty liver disease.
Chávez-Tapia NN; Uribe M; Ponciano-Rodríguez G; Medina-Santillán R; Méndez-Sánchez N
Ann Hepatol; 2009; 8 Suppl 1():S9-17. PubMed ID: 19381119
[TBL] [Abstract][Full Text] [Related]
70. Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species.
Wei Y; Chen K; Whaley-Connell AT; Stump CS; Ibdah JA; Sowers JR
Am J Physiol Regul Integr Comp Physiol; 2008 Mar; 294(3):R673-80. PubMed ID: 18094066
[TBL] [Abstract][Full Text] [Related]
71. CTRP1 in Liver Disease.
Shabani P; Emamgholipour S; Doosti M
Adv Clin Chem; 2017; 79():1-23. PubMed ID: 28212710
[TBL] [Abstract][Full Text] [Related]
72. Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics.
Di Sessa A; Riccio S; Pirozzi E; Verde M; Passaro AP; Umano GR; Guarino S; Miraglia Del Giudice E; Marzuillo P
World J Gastroenterol; 2021 Jul; 27(25):3815-3824. PubMed ID: 34321846
[TBL] [Abstract][Full Text] [Related]
73. Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance.
Petersen MC; Shulman GI
Trends Pharmacol Sci; 2017 Jul; 38(7):649-665. PubMed ID: 28551355
[TBL] [Abstract][Full Text] [Related]
74. Immune regulation of glucose and lipid metabolism.
Ota T
Diabetol Int; 2017 Aug; 8(3):257-267. PubMed ID: 30603331
[TBL] [Abstract][Full Text] [Related]
75. Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration.
Kelty TJ; Dashek RJ; Arnold WD; Rector RS
Semin Liver Dis; 2023 Feb; 43(1):77-88. PubMed ID: 36764305
[TBL] [Abstract][Full Text] [Related]
76. Innate Immunity and MASLD.
Meyer M; Schwärzler J; Jukic A; Tilg H
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672492
[TBL] [Abstract][Full Text] [Related]
77. The regulatory role of metabolic organ-secreted factors in the nonalcoholic fatty liver disease and cardiovascular disease.
Qin L; Wu J; Sun X; Huang X; Huang W; Weng C; Cai J
Front Cardiovasc Med; 2023; 10():1119005. PubMed ID: 37180779
[TBL] [Abstract][Full Text] [Related]
78. The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease-The Transition from an Adipocentric to Liver-Centric Approach.
Vesković M; Šutulović N; Hrnčić D; Stanojlović O; Macut D; Mladenović D
Curr Issues Mol Biol; 2023 Nov; 45(11):9084-9102. PubMed ID: 37998747
[TBL] [Abstract][Full Text] [Related]
79. Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance.
Ilan Y
Am J Physiol Gastrointest Liver Physiol; 2016 Jun; 310(11):G1102-17. PubMed ID: 27173510
[TBL] [Abstract][Full Text] [Related]
80. Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?
Yilmaz Y
World J Hepatol; 2012 Dec; 4(12):332-4. PubMed ID: 23355910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
